Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S

DOI: 10.1007/s40273-017-0571-8
Published: 2018 Feb
Container: PharmacoEconomics
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40273-017-0571-8,
  title = {Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.},
  author = {Bermejo I and Stevenson M and Cooper K and Harnan S and Hamilton J and Clowes M and Carroll C and Harrison T and Saha S},
  year = {2018},
  journal = {PharmacoEconomics},
  doi = {10.1007/s40273-017-0571-8},
  url = {https://doi.org/10.1007/s40273-017-0571-8}
}

RIS

TY  - JOUR
TI  - Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
AU  - Bermejo I
AU  - Stevenson M
AU  - Cooper K
AU  - Harnan S
AU  - Hamilton J
AU  - Clowes M
AU  - Carroll C
AU  - Harrison T
AU  - Saha S
PY  - 2018
JO  - PharmacoEconomics
DO  - 10.1007/s40273-017-0571-8
UR  - https://doi.org/10.1007/s40273-017-0571-8
ER  -

APA

I, B., M, S., K, C., S, H., J, H., M, C., C, C., T, H., & S, S. (2018). Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics. https://doi.org/10.1007/s40273-017-0571-8

Source records

pubmed · retrieved 2026-09-26T19:37:32.440Z